VCP
BMY.RT

Verus Capital Partners’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Verus Capital Partners’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		$1K Hold
210
– – ﹤0.01% 1455
2019
Q4 		$1K Buy
+210
New +$546 ﹤0.01% 1511

Other funds holding BMY.RT

PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Verus Capital Partners's BMY.RT Position: Q1 2020 in Review

Verus Capital Partners held its Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) position steady in Q1 2020 at 210 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #1455.

Verus Capital Partners first reported a position in BMY.RT in Q4 2019 and has held it in 2 quarters since. 581 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2020.

  • Verus Capital Partners held 210 shares of Bristol-Myers Squibb Company Contingent Value Rights worth $1K as of Q1 2020.
  • Verus Capital Partners left its Bristol-Myers Squibb Company Contingent Value Rights share count unchanged in Q1 2020.
  • Bristol-Myers Squibb Company Contingent Value Rights made up ﹤0.01% of Verus Capital Partners's portfolio in Q1 2020, its #1455 holding.
  • Verus Capital Partners first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and has held it in 2 quarters since.
  • 581 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2020.

Based on Verus Capital Partners's 13F filing for Q1 2020, filed 26 May 2020.